Formulation of Kaempferol in Nanostructured Lipid Carriers (NLCs): A Delivery Platform to Sensitization of MDA-MB468 Breast Cancer Cells to Paclitaxel

Drug delivery-based nanoparticle has been developing as a widespread innovation in cancer treatment protocols. Here, we investigated the role of Kaempferol (KAE) loaded in nanostructured lipid carriers (NLCs) to promote cytotoxicity, efficacy, and paclitaxel-dependent apoptosis in MDA-MB 468 breast cancer cells. Particle size distribution, scanning electron microscopy (SEM), zeta potential, and cellular uptake were harnessed to optimize and characterize of KAE -loaded NLCs. MTT assay was used to measure the cellular proliferation of cancer cells. The clarification of early and late apoptosis and their gene expression patterns was assessed by Annexin V/PI staining and real-time PCR, respectively. SEM images offered us a nasty particle size of 80 ± 3 nm to the Kaempferol formulated into NLCs. The IC50 values for KAE and paclitaxel determined 44 ± 0.52 μM and 1.75 ± 0.36 nM, respectively. The moderated cell proliferation from 56 ± 26.8% to 44 ± 3.9% (p < 0.05) was demonstrated by KAE loaded NLCs. Co-administration of KAE-loaded nanoparticles and paclitaxel into cancer cells significantly strengthens the percentage of apoptosis (p < 0.05). Our results recommend that KAE incorporated into NLCs as an anti-cancer adjuvant is a powerful technique that may be a useful delivery system to enhance chemotherapy agents' effect on breast cancer cells.